Document Detail


Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis.
MedLine Citation:
PMID:  20806430     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To demonstrate the therapeutic effect of probiotics in patients with ulcerative colitis (UC), and their effect on inflammatory mediators and nuclear factor (NF)-kappaB activation in these patients.
METHODS: Thirty patients with mild to moderate UC were randomly classified into two groups: sulfasalazine group, who received sulfasalazine 2400 mg/d; and probiotic group, who received sulfasalazine 2400 mg/d with probiotic. The patients were investigated before and after 8 wk of treatment with probiotic (Lactobacillus delbruekii and Lactobacillus fermentum). Colonic activity of myeloperoxidase (MPO) was assayed with UV spectrophotometry, the colonic content of interleukin (IL)-6 was determined by enzyme-linked immunosorbent assay (ELISA), fecal calprotectin was determined by ELISA, and expression of NF-kappaB p65 and tumor necrosis factor (TNF)-alpha proteins in colonic tissue was identified by immunohistochemistry and reverse transcription polymerase chain reaction, respectively.
RESULTS: At the start of the study, colonic mucosal injury and inflammation were demonstrated in UC patients by hematoxylin and eosin staining, and an increase in colonic MPO activity, fecal calprotectin, and expression of colonic TNF-alpha and NF-kappaB p65 proteins. The use of probiotic for 8 wk significantly ameliorated the inflammation by decreasing the colonic concentration of IL-6, expression of TNF-alpha and NF-kappaB p65, leukocyte recruitment, as demonstrated by a decrease in colonic MPO activity, and the level of fecal calprotectin compared to sulfasalazine group and the control group (P < 0.05).
CONCLUSION: Oral supplementation with probiotics could be helpful in maintaining remission and preventing relapse of UC.
Authors:
Sahar K Hegazy; Mohamed M El-Bedewy
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  World journal of gastroenterology : WJG     Volume:  16     ISSN:  1007-9327     ISO Abbreviation:  World J. Gastroenterol.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-31     Completed Date:  2010-12-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883448     Medline TA:  World J Gastroenterol     Country:  China    
Other Details:
Languages:  eng     Pagination:  4145-51     Citation Subset:  IM    
Affiliation:
Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta 8130, Egypt. saharhegazy96@yahoo.co.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Colitis, Ulcerative / drug therapy,  metabolism*
Feces
Female
Humans
Interleukin-6 / metabolism*
Intestinal Mucosa / drug effects,  metabolism
Lactobacillus delbrueckii / physiology
Lactobacillus fermentum / physiology
Leukocyte L1 Antigen Complex / metabolism
Male
Middle Aged
NF-kappa B / metabolism*
Peroxidase / metabolism
Probiotics / pharmacology*,  therapeutic use
Sulfasalazine / therapeutic use
Treatment Outcome
Tumor Necrosis Factor-alpha / metabolism*
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Interleukin-6; 0/Leukocyte L1 Antigen Complex; 0/NF-kappa B; 0/Tumor Necrosis Factor-alpha; 599-79-1/Sulfasalazine; EC 1.11.1.7/Peroxidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Design of 16S rRNA gene primers for 454 pyrosequencing of the human foregut microbiome.
Next Document:  Chemoprotective effects of curcumin in esophageal epithelial cells exposed to bile acids.